Diagnostic and Prognostic Nomograms for Bone Metastasis in Patients With Newly Diagnosed Renal Cell Carcinoma

Zhangheng Huang
Department of Orthopedic, Affiliated Hospital of Chengde Medical University

Chuan Hu
Qingdao University medical college, Qingdao, Shandong, China

Yuexin Tong
Department of Orthopedic, Affiliated Hospital of Chengde Medical University

Chengliang Zhao (✉️ 38221965@qq.com)
Department of Orthopedic, Affiliated Hospital of Chengde Medical University

Research

Keywords: Renal cell carcinoma, Bone metastasis, Nomogram, SEER

Posted Date: September 21st, 2020

DOI: https://doi.org/10.21203/rs.3.rs-76729/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Bone metastasis (BM) is one of the common sites of renal cell carcinoma (RCC), and patients with BM have a worse prognosis than those without it. We aimed to develop two nomograms to quantify the risk of BM and predict the prognosis of RCC patients with BM.

Methods

We reviewed patients with newly diagnosed RCC with BM in the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015. Multivariate logistic regression analysis was used to determine independent predictors of BM in RCC patients. Univariate and multivariate Cox proportional hazards regression analysis was used to determine independent prognostic factors for BM in RCC patients. Diagnostic and prognostic nomograms were established and evaluated by calibration curve, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA).

Results

The study included 37554 patients newly diagnosed with RCC in the SEER database, 537 of whom were BM patients. Risk factors for BM in RCC patients included sex, tumor size, liver metastasis, lung metastasis, brain metastasis, N stage, T stage, histologic type, and grade. Independent prognostic factors for RCC with BM were grade, histologic type, N stage, surgery, brain metastasis, and lung metastasis. Calibration, ROC curve, and DCA showed that both diagnostic and prognostic nomograms showed good performance.

Conclusions

Diagnostic and prognostic nomograms were established to predict the risk of BM in RCC and the prognosis of RCC with BM, respectively. These nomograms strengthen each patient's prognosis-based decision making, which is of great significance in improving the prognosis of patients.

Introduction

Renal cell carcinoma (RCC) is one of the most common cancers worldwide, with approximately 403,262 new cases and 17,598 deaths in 2018[1]. Bone is a common site of metastasis in RCC and is present in about one-third of patients at the time of diagnosis[2, 3]. Bone metastasis (BM) from RCC are predominantly osteolytic and can lead to the development of skeletal-related diseases, which can reduce the quality of life and prognosis of the patients[4, 5]. The median overall survival (OS) of RCC patients with BM at diagnosis has been reported to be only 12 months to 28 months[6, 7]. Therefore, it is import to clearly understand the BM in RCC patients.
The TNM staging system is widely used to assess the prognosis of cancer patients, and clinicians use it to develop treatment plans[8]. Notably, studies have shown that race, sex, age, and tumor size may also affect the prognosis of patients with RCC[9-11]. The TNM staging system just relies on three pathological indicators and ignores other prognostic factors, thereby reducing the accuracy of prognostic prediction for RCC patients. Therefore, it is necessary to combine clinicopathology and other prognosis-related variables to construct a tool to accurately predict the prognosis and overcome the limitations of the traditional TNM staging system.

The nomogram is a tool that combines multiple biological and clinical variables to predict specific endpoints and has been widely used in recent years to predict the prognosis of cancer prognosis[12-14]. By combining these important variables, the nomograms can individually estimate of the probability of events over time, such as the OS of cancer patients. In addition, for estimating the survival rate of individual cancer patients, the nomogram showed higher accuracy than the TNM staging system in several cancers [15].

Risk factors and prognosis-related factors for BM in RCC have been reported in several previous studies[16-18]. However, no studies have focused on constructing predictive models for the risk and prognosis of BM in RCC, which means that the probability of outcome cannot be quantified. Therefore, based on the data from the Surveillance, Epidemiology, and End Results (SEER) database, we aimed to develop two nomograms for predicting the risk of BM with newly diagnosed RCC and the OS of newly RCC patients with BM, respectively.

**Methods**

**Study population selection**

The SEER database covers approximately 28% of cancer registries in the United States[19]. The data contained in this study were downloaded from the SEER * Stat software version 8.3.6. Analysis of unidentified data from the SEER database is exempt from medical ethics review and does not require informed consent. The SEER database provides clinical information on cancer patients that greatly facilitate clinical research. Patients diagnosed before 2010 were excluded because the SEER database did not record information on distant metastases until 2010. In addition, to ensure adequate follow-up time, patients diagnosed after 2015 are not included. Therefore, only patients diagnosed with RCC between 2010 and 2015 were considered in this study.

Inclusion criteria were as follows: (1) RCC as the first primary tumor, (2) patients with a histologic diagnosis of RCC, (3) patients with complete clinicopathological features, demographic information, and follow-up information. In addition, patients who were certified by autopsy or death were excluded from this study. Finally, a total of 37554 patients with RCC were enrolled to study the risk factors for BM in patients with RCC and to establish a diagnostic nomogram. Subsequently, RCC patients with BM with survival time ≥ one month, specific treatment information, including surgery, radiotherapy, and chemotherapy, were used to form a new cohort to explore the prognostic factors for RCC patients with BM.
and develop a prognostic nomogram. Ultimately, 537 patients were used to study prognostic factors in patients with BM from RCC. Patients in each cohort were randomized into training and validation cohorts in a 7:3 ratio. In this study, patients in the training cohort were used to construct the predicted nomogram, while patients in the validation cohort were used to validate the constructed nomogram.

Data collection

Based on patient-specific information from the SEER database, we selected 14 variables to identify risk factors for BM in RCC, including age, sex, race, tumor size, histologic type, grade, laterality, T stage, N stage, distant metastatic site (lung, brain, liver), insurance status, and marital status. In addition to the aforementioned variables, information on surgery, radiotherapy, and chemotherapy are included to study the factors that influence the prognosis of RCC patients with BM. Histologic type was defined by following ICD-O-3 codes: clear cell (8310/3, 8313/3), papillary (8260/3), chromophobe (8317/3, 8270/3), collecting duct (8319/3). Regarding to marital status, we excluded misleading data on unmarried or domestic partners and then included "unmarried", "separated", "single" and "widowed" all in the unmarried group. Insurance status is divided into insured and uninsured, with both "insured" and "insured/unspecific" included in the insured group. All cases in this study were staged using version 7 of the American Joint Committee on Cancer TNM staging system. In the survival analysis, the primary endpoint of our study was OS, which was defined as the date from diagnosis to death (for any reason) or the date of the last follow-up.

Statistical analysis

This study used SPSS 25.0 and R software (version 3.6.1) for statistical analysis. A comparison of continuous data was done by an independent t-test, while the chi-square test was used for categorical data. Variables with P values <0.05 in univariate analysis were incorporated into multivariate logistic regression analysis to identify independent risk factors for BM in newly diagnosed RCC patients. At the same time, univariate Cox proportional hazards regression analysis was used to determine OS-related variables. Significant variables in the univariate Cox proportional hazards regression analysis were then included in the multivariate Cox proportional hazards regression analysis to identify independent prognostic factors in RCC patients with BM.

Diagnostic and prognostic nomograms were developed separately based on independent BM-related predictors and prognostic factors using the "rms" package in R software. Receiver operating characteristic (ROC) curves for two nomograms were generated and the corresponding area under the curve (AUC) was used to evaluate the discrimination of nomograms. The clinical application value of the nomogram model was evaluated by calibration curve and decision curve analysis (DCA). Finally, all patients were divided into high-risk and low-risk groups according to the median of risk score, and survival curves were used to verify the prognostic value of the nomogram [20].

Results
The characteristics of the study population

The workflow of our study is illustrated in Figure 1. A total of 37,554 RCC patients from the SEER database were included. Furthermore, 26,290 and 11,264 patients were included in the training and validation cohorts, respectively. Clinicopathological information of 26,290 RCC patients are shown in Table 1.

Risk factors of BM in RCC patients

To identify BM-related variables in NSCLC patients, 14 factors were analyzed. The results showed that ten predictors were related to the BM in RCC patients, including race, sex, grade, histologic type, T stage, N stage, brain metastasis, liver metastasis, lung metastasis, and tumor size (Table 1). Subsequently, the above variables were included in the multivariate logistic regression analysis, which showed that tumor size, liver metastasis, lung metastasis, brain metastasis, N stage, T stage, histologic type, and grade were independent predictors of RCC with BM (Table 2).

Development and validation of a diagnostic nomogram for BM in newly diagnosed RCC patients

Based on eight independent BM-related variables, a nomogram was constructed to assess the risk of BM in newly diagnosed RCC patients (Figure 2). The AUCs of the nomogram were 0.865 and 0.859 in the training and validation cohorts, respectively, showing good discrimination (Figure 3A and Figure 4A). Both in the training and validation cohorts, the calibration curve showed that the observations are highly consistent with the predicted results (Figure 3B and Figure 4B). Moreover, DCA indicated that the diagnostic nomogram performs well in clinical practice (Figure 3C and Figure 4C). More importantly, ROC curves were also generated for each independent predictor variable. As shown in Figure 5, the AUC of the nomogram is higher than the AUCs of all independent variables in both training and validation cohorts, indicating a significant advantage in the accuracy of predictions using the nomogram compared to predictions using individual independent predictors.

Prognostic factors for RCC patients with BM

According to the selection process, a total of 537 patients with BM were included in our research. Meanwhile, 377 patients were incorporated into the training cohort, and the remaining 160 patients were incorporated into the validation cohort. Univariate and multivariate Cox proportional hazards regression analysis was performed to screen for prognostic factors. Univariate Cox proportional hazards regression analysis showed that grade, T stage, histologic type, N stage, surgery, chemotherapy, brain metastasis, liver metastasis, and lung metastasis are OS-related factors (Table 3). After controlling for confounding variables using multivariate Cox proportional hazards regression analysis, grade, histologic type, N stage, surgery, brain metastasis, and lung metastasis were identified as independent prognostic factors in RCC patients with BM (Table 3). As shown in Figure 6, the survival curve analysis further demonstrated the impact of screened independent prognostic factors on the OS of RCC patients with BM.

Prognostic nomogram for RCC patients with BM
A prognostic nomogram of RCC patients with BM based on six independent prognostic factors was established (Figure 7). The ROC curve showed that the AUCs at 1, 2, and 3 years were 0.711, 0.772, and 0.766 in the training cohort and 0.684, 0.663, and 0.691 in the validation cohort (Figure 8A and 8C). Patients in the cohort were divided into high- and low-risk groups according to the median of risk score. By depicting the Kaplan-Meier survival curve, we can find that patients in the high-risk group showed a worse prognosis than patients in the low-risk group (Figure 8B and 8D). In addition, we further compared the discrimination between the nomogram and the independent prognostic factors and the results showed that the AUC of the nomogram was higher than the AUCs of all independent factors at 1, 2, and 3 years, both in the training cohort and in the validation cohort (Figure 9). Calibration curves of predicting 1, 2, and 3-year OS probabilities also show good agreement between the OS predicted by the prognostic nomogram and the actual results (Figure 10 A and 10B). The DCA was used to evaluate the clinical utility of a nomogram. As shown in Figure 10, the prognostic nomogram shows a significant positive net benefit over a wide range of mortality risks, suggesting its high clinical utility in predicting OS in RCC patients with BM.

Discussion

RCC accounts for 3% of all malignancies and 80%-85% of primary renal cancer[21]. Bone is the second most common site of metastasis in RCC patients, following lung[22, 23]. In the present study, we constructed diagnostic and prognostic nomograms to predict the risk of BM in newly diagnosed RCC patients and the OS of RCC patients with BM by analyzing a large number of data, respectively. We believe that two nomograms representing OS and distant metastasis, respectively, are complementary and can increase their clinical value in patients with RCC. The total score can be calculated by obtaining data for the corresponding variable on the nomogram for each RCC patient. The risk of BM can then be easily identified on the diagnostic nomogram, identifying patients in the high-risk group and guiding clinical practice in early intervention. Similarly, the prognosis of RCC patients with BM can be determined from the prognostic nomogram. In the validation of the two nomograms, the two nomograms showed excellent performance in BM risk assessment and OS prediction in RCC patients, respectively, which will enable more accurate personalized clinical decision-making and monitoring.

Despite the poor prognosis of RCC patients with BM, early detection of BM may be critical for patients with RCC to receive appropriate treatment. Therefore, exploring the risk factors for BM in RCC patients is important for clinical decision-making. At the molecular level, cadherin-11, transforming growth factor-β, insulin-like growth factor, and fibroblast growth factor has been reported to be associated with BM in RCC patients[24, 25]. Nevertheless, these biomarkers are difficult and impractical to apply immediately to clinical decision-making. In addition, regarding some practical clinical features, sex, T stage, N stage, grade, liver metastasis, lung metastasis, brain metastasis, and histologic type have been reported as relevant risk factors for BM in newly diagnosed RCC[18]. To date, however, predictive models have not been developed, which means that it is not possible to identify an individual’s risk of BM by combining all independent predictors associated with BM. The results of the present study showed tumor size, liver metastasis, lung metastasis, brain metastasis, N stage, T stage, histologic type, and grade was a
significant predictor of BM in RCC. The association between these factors and BM in RCC patients has been reported in previous studies. Previous studies have confirmed the relationship between tumor grade, TNM staging, and BM in newly diagnosed RCC patients[18]. TNM staging is widely used in the assessment of prognosis in cancer patients. Notably, a greater contribution of TNM staging was shown in both the diagnostic nomogram and the prognostic nomogram. With increasing tumor size, an increasing number of lymph node metastases, and the presence of distant organ metastases, the risk of BM in RCC and the risk of death in RCC patients with BM are significantly increased.

In addition, our study found a poor prognosis of RCC BM patients with lymph node metastasis, brain metastasis, lung metastasis, without surgery, poor tumor differentiation, and histologic type of the collecting duct. A prognostic nomogram was established based on six independent prognostic factors. The results suggested that a nomogram can be an effective tool for identifying high-risk patients. The impact of histologic type on metastatic potential and prognosis of metastatic patients is often overlooked when discussing treatment options. In this study, collecting duct RCC had a higher incidence of BM and a worse prognosis compared to other renal cancer subtypes. Collecting duct RCC is reported to be a rare entity that occurs in <2% of patients with kidney cancer, often resulting in a poor prognosis[26]. In addition, the above correlation has been confirmed in previous studies[27, 28]. The relationship between lung metastasis, brain metastasis, surgery, and prognosis in patients with RCC has also been widely reported in previous studies. Lin et al. reported a better prognosis in patients with only BM than in patients with concomitant pulmonary metastases, and a significantly better prognosis for patients with single BM than in patients with multiple bone and/or visceral metastasis[29]. Similarly, Toyoda et al. reported a shorter median survival in patients with extra-BM compared to those without (8 vs 33 months, p=0.0084)[30]. Surprisingly, contrary to previous reports, the presence of liver metastasis was not an independent prognostic factor in our study [31, 32]. However, this is consistent with what has been reported by Santoni et al.[17]. For the treatment of RCC patients with BM, recent consensus suggests the use of a multimodal treatment strategy that includes extensive resection of the lesion, radiotherapy, systemic therapy, and other local treatment options[33]. Of RCC patients with BM, the goal of surgical treatment is to improve the prognosis, local tumor control, pain relief, and preservation or reconstruction of function. Based on the results, we found that surgery was not only an independent prognostic factor, but that patients who had surgery showed a better prognosis. As reported in several studies, surgical removal of isolated or minimally metastatic lesions can improve the prognosis of patients with BM, thus providing a multidisciplinary team to support the treatment plan for these patients[34-36]. Although renal cancer is usually not sensitive to radiotherapy and chemotherapy, palliative radiotherapy has the potential to significantly relieve local symptoms and improve quality of life[37, 38]. Tyrosine kinase inhibitors (TKIs) and anti-vascular endothelial growth factor antibodies are now widely used as first- and second-line therapy for advanced RCC. Direct evidence on the effects of targeted drugs on BM is currently limited to a few studies that have shown that TKIs can prolong the mean time to progression of existing bone lesions and reduce the formation of new bone lesions[2, 39]. Unfortunately, the SEER database does not contain specific analyses of targeted therapies, chemotherapy, radiotherapy, and we are unable to
analyze their influence on prognosis in further detail. In addition, further research on important prognostic factors for OS with BM in RCC is necessary.

However, some limitations of our study should be noted. First, information collected in the SEER database is about the disease at the time of the first diagnosis and does not record BM that occurred later. Secondly, the prognostic impact of the amount of BM should not be overlooked, but there is no record of this in the SEER database. Third, we did not have access to some biomarkers from the SEER database, such as transforming growth factor-β, insulin-like growth factor, and fibroblast growth factor. Fourth, this was a retrospective study in which selection bias was inevitable and information on detailed treatment was not available in the SEER database.

**Conclusion**

Two nomograms we created could be used as a supportive graphic tool in RCC patients to help clinicians distinguish, assess, and evaluate the risk and prognosis of RCC with BM. At the same time, when faced with individualized condition consultation, these nomograms are useful methods to provide prognostic information to clinical patients, and strengthen each patient's prognosis-based decision making, which is of great significance in improving the prognosis of patients.

**Abbreviations**

RCC: renal cell carcinoma; BM: bone metastasis; OS: overall survival; SEER: Surveillance, Epidemiology and End Results; ROC: receiver operating characteristic; AUC: area under the curve; DCA: decision curve analysis; TKIs: Tyrosine kinase inhibitors.

**Declarations**

**Ethics approval and consent to participate**

The research didn't involve animal experiments and human specimens, no ethics related issues.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The data of this study are from SEER database.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**
We received no external funding for this study.

Author Contributions
ZH H, CL Z conceived of and designed the study. ZH H, C H and YX T performed literature search. ZH H, C H generated the figures and tables. ZH H, C H analyzed the data. ZH H wrote the manuscript and CL Z critically reviewed the manuscript. ZH H, CL Z supervised the research.

Acknowledgements
None

References
1. F B, J F, I S, RL S, LA T, A J: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018, 68(6):394-424.
2. SL W, JE B: Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer treatment reviews 2012, 38(4):284-291.
3. K G, JD M, JZ L, MW R, C C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer treatment reviews 2008, 34(3):193-205.
4. J Z, N A, RE C, BW H: The skeletal metastatic complications of renal cell carcinoma. International journal of oncology 2001, 19(2):379-382.
5. DY H, W X, GA B, U V, MH T, J K, F D, L W, C K, BI R et al: Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 2011, 117(12):2637-2642.
6. T Y, S U, S Y, J Y, K S, S T, K H, I F: Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clinical & experimental metastasis 2011, 28(4):405-411.
7. Toyoda Y, Shinohara N, Harabayashi T, Abe T, Akino T, Sazawa A, Nonomura K: Survival and Prognostic Classification of Patients with Metastatic Renal Cell Carcinoma of Bone. European Urology 2007, 52(1):163-169.
8. HB B: Outcome prediction and the future of the TNM staging system. Journal of the National Cancer Institute 2004, 96(19):1408-1409.
9. EJ J, HJ L, C K, JH K, KC M: Young age is independent prognostic factor for cancer-specific survival of low-stage clear cell renal cell carcinoma. Urology 2009, 73(1):137-141.
10. J W, P Z, G Z, H W, W G, B D, H Z, G S, Y S, Y Z et al: Renal cell carcinoma histological subtype distribution differs by age, gender, and tumor size in coastal Chinese patients. Oncotarget 2017, 8(42):71797-71804.
11. CT L, J K, PA F, P R: Mode of presentation of renal cell carcinoma provides prognostic information. Urologic oncology 2002, 7(4):135-140.
12. W Z, Y H, H C, N W, W X, Y L, X J, W S, S W: Nomogram application to predict overall and cancer-specific survival in osteosarcoma. Cancer management and research 2018, 10:5439-5450.

13. SY K, MJ Y, YI P, MJ K, BH N, SR P: Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2018, 21(3):453-463.

14. MW K, V R, RJ M, J K, P R: A postoperative prognostic nomogram for renal cell carcinoma. The Journal of urology 2001, 166(1):63-67.

15. N P, J L, Y X, W L, Y F, X H, G Z, L Z, A N, H Y et al: Comparison of prognostic prediction between nomogram based on lymph node ratio and AJCC 8th staging system for patients with resected pancreatic head carcinoma: a SEER analysis. Cancer management and research 2018, 10:227-238.

16. H K, S K, Y Y, M S, T T, M S, T F, H F, Y E, H N et al: Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors? The Journal of urology 2011, 185(5):1611-1614.

17. M S, A C, G P, C P, T I, S B, FM G, A F, A B, R B et al: Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? Journal of experimental & clinical cancer research : CR 2015, 34:10.

18. Q G, C Z, X G, F T, Y X, G F, X H, Z R, H Z, P Z et al: Incidence of bone metastasis and factors contributing to its development and prognosis in newly diagnosed renal cell carcinoma: a population-based study. Cancer management and research 2018, 10:2935-2944.

19. KA C, LA R, BK E: The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer 2014:3755-3757.

20. J R, JA C: Kaplan-Meier curve. The British journal of surgery 2017, 104(4):442.

21. J R, K D, JA G: Renal Cell Carcinoma with monosomy 8: A Case Series and Review of the Literature. Journal of the Association of Genetic Technologists 2018, 44(1):5-9.

22. B P, E D, SP LM, L B, MP P, Y A, A dlT, S M, F C, S M: Identification of a novel biomarker signature associated with risk for bone metastasis in patients with renal cell carcinoma. The International journal of biological markers 2010, 25(2):112-115.

23. T C, Z K, H G, GS K, RJ H, NE F: Metastatic renal cell carcinoma: Patterns and predictors of metastases-A contemporary population-based series. Urologic oncology 2017, 35(11):661.e667-661.e614.

24. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M: Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. Journal of Biological Chemistry 1986, 261(27):12665-12674.

25. Chen S, Kuo P: Bone Metastasis from Renal Cell Carcinoma. International Journal of Molecular Sciences 2016, 17(6):987.

26. JL W, MC R, J H, DW L: Effect of collecting duct histology on renal cell cancer outcome. The Journal of urology 2009, 182(6):2595-2599.
27. N T, S N, O M, Y N, S O, T I: Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. *The Journal of urology* 2006, **176**(1):40-43; discussion 43.

28. PI K, QD T, N R-L, A dIT, G N, J T, L C, V F, W A, L S et al: Collecting duct renal cell carcinoma: a matched analysis of 41 cases. *European urology* 2007, **52**(4):1140-1145.

29. PP L, AN M, VO L, CP C, SM T, NM T, AW Y: Patient survival after surgery for osseous metastases from renal cell carcinoma. *The Journal of bone and joint surgery American volume* 2007, **89**(8):1794-1801.

30. Y T, N S, T H, T A, T A, A S, K N: Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. *European urology* 2007, **52**(1):163-168.

31. RJ M, B E, P T, TE H, MD M, S N, S O, ME G, J T, S H et al: Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. *The Lancet Oncology* 2013, **14**(6):552-562.

32. RR M, N K, W X, JL L, JJ K, GA B, MJ M, L W, S S, UN V et al: Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. *European urology* 2014, **65**(3):577-584.

33. V G, B E, A B, A F, T G, T D, M P, HR D, KA G, RH G et al: An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. *Nature reviews Urology* 2018, **15**(8):511-521.

34. A F, M S, L W, M S, A B-M, V J, HR D: Bone metastases from renal cell carcinoma: patient survival after surgical treatment. *BMC musculoskeletal disorders* 2010, **11**:145.

35. B F, RT T, MG R: Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. *Clinical orthopaedics and related research* 2005(431):187-192.

36. AL A, SA B, CM L, BA C, BC L, ML B: Survival after complete surgical resection of multiple metastases from renal cell carcinoma. *Cancer* 2011, **117**(13):2873-2882.

37. J L, D H, E C, A B, P C, D T, M OB, C D, C H, P W et al: A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. *Cancer* 2005, **104**(9):1894-1900.

38. D W, L H, L G, M G, A S, N J: The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. *Clinical oncology (Royal College of Radiologists (Great Britain))* 2003, **15**(7):400-407.

39. J Z, P N, P L, S O, A W-G, E K, B O, C S: Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. *Journal of cancer research and clinical oncology* 2010, **136**(3):371-378.

**Tables**
Table 1: The result of univariate analysis

|                          | Without BM | With BM | \(\chi^2\) | P    |
|--------------------------|------------|---------|------------|------|
| **Age**                  |            |         |            |      |
| ≥65                      | 14388(55.7%) | 264(58.5%) | 1.463 | 0.226 |
| ≥65                      | 11451(44.3%) | 187(41.5%) |       |      |
| **Sex**                  |            |         |            |      |
| Female                   | 9111 (35.3%) | 132(29.3%) | 6.982 | 0.008 |
| Male                     | 16728(64.7%) | 319(70.7%) |       |      |
| **Race**                 |            |         |            |      |
| Black                    | 2648(10.2%) | 30(6.7%) | 6.289 | 0.043 |
| Other                    | 1585(6.1%) | 28(6.2%) |       |      |
| White                    | 21606(83.6%) | 393(87.1%) |   |      |
| **Grade**                |            |         |            |      |
| I-II                     | 16818(65.1%) | 136(30.2%) | 236.193 | 0.000 |
| III-IV                   | 9021(34.9%) | 315(69.8%) |       |      |
| **T stage**              |            |         |            |      |
| T1-2                     | 20760(80.3%) | 182(40.4%) | 437.434 | 0.000 |
| T3-4                     | 5079(19.7%) | 269(59.6%) |       |      |
| **Laterality**           |            |         |            |      |
| Left                     | 12723(49.2%) | 236(52.3%) | 1.692 | 0.193 |
| Right                    | 13116(50.8%) | 215(47.7%) |       |      |
| **Histologic type**      |            |         |            |      |
| CP                       | 1416(5.5%) | 6(1.3%) | 79.734 | 0.000 |
| CC                       | 20244(78.3%) | 407(90.2%) |       |      |
| CD                       | 54(0.2%) | 7(1.6%) |       |      |
| PL                       | 4125(16.0%) | 31(6.9%) |       |      |
| **Tumor size, cm**       |            |         |            |      |
| ≥4                       | 12087(46.8%) | 39(8.6%) | 392.797 | 0.000 |
| 4-7     | 8559(33.1%) | 167(37.0%) |
|---------|-------------|------------|
| ≥7      | 5193(20.1%) | 245(54.3%) |

| N stage       |        |          |
|---------------|--------|----------|
| N0            | 25218(97.6%) | 345(76.5%) |
| N1            | 621(2.4%) | 106(23.5%) |

| Brain metastasis |        |          |
|------------------|--------|----------|
| No               | 25741(99.6%) | 408(90.5%) |
| Yes              | 98(0.4%) | 43(9.5%)  |

| Liver metastasis |        |          |
|------------------|--------|----------|
| No               | 25707(99.5%) | 404(89.6%) |
| Yes              | 132(0.5%) | 47(10.4%) |

| Lung metastasis |        |          |
|-----------------|--------|----------|
| No              | 25139(97.3%) | 274(60.8%) |
| Yes             | 700(2.7%) | 177(39.2%) |

| Insurance status |        |          |
|------------------|--------|----------|
| No               | 750(2.9%) | 14(3.1%)  |
| Yes              | 25089(97.1%) | 437(96.9%) |

| Marital status  |        |          |
|-----------------|--------|----------|
| No              | 8109(31.4%) | 123(27.3%) |
| Yes             | 17730(68.6%) | 328(72.7%) |

BM: bone metastasis, CP: chromophobe, CC: clear cell, CD: collecting duct, PL: papillary
| Variables                     | OR (95% CI)         | P value |
|-------------------------------|---------------------|---------|
| Grade                         |                     |         |
| G1-2 Reference                |                     |         |
| G3-4                          | 1.749 (1.388–2.204) | 0.000   |
| T stage                       |                     |         |
| T1-2 Reference                |                     |         |
| T3-4                          | 1.748 (1.379–2.216) | <0.001  |
| Histologic type               |                     |         |
| CP Reference                  |                     |         |
| CC                            | 3.300 (1.459–7.466) | 0.004   |
| CD                            | 4.216 (1.245–14.277) | 0.021   |
| PL                            | 1.850 (0.762–4.490) | 0.174   |
| Tumor size, cm                |                     |         |
| ≤ 4                           | Reference           |         |
| 4-7                           | 3.937 (2.745–5.648) | 0.000   |
| ≥ 7                           | 3.510 (2.374–5.189) | 0.000   |
| N stage                       |                     |         |
| N0 Reference                  |                     |         |
| N1                            | 2.654 (2.005–3.513) | 0.000   |
| Brain metastasis              |                     |         |
| No Reference                  |                     |         |
| Yes                           | 4.283 (2.780–6.598) | 0.000   |
| Liver metastasis              |                     |         |
| No Reference                  |                     |         |
| Yes                           | 3.309 (2.211–4.952) | 0.000   |
| Lung metastasis               |                     |         |
| No Reference                  |                     |         |
| Yes                           | 5.351 (4.123–6.946) | 0.000   |
|                | Univariate Cox analysis |                      |                      | Multivariate Cox analysis |                      |                      |
|----------------|-------------------------|----------------------|----------------------|---------------------------|----------------------|----------------------|
|                | HR         | 95%CI     | P       | HR         | 95%CI     | P       |
| Age            |            |           |         |            |           |         |
| <65            |            |           |         |            |           |         |
| ≥65            | 1.026      | 0.798     | 1.319   | 0.844      |           |         |
| Race           |            |           |         |            |           |         |
| Black          |            |           |         |            |           |         |
| Other          | 1.660      | 0.913     | 3.020   | 0.097      |           |         |
| White          | 1.293      | 0.827     | 2.023   | 0.260      |           |         |
| Sex            |            |           |         |            |           |         |
| Female         |            |           |         |            |           |         |
| Male           | 1.109      | 0.847     | 1.452   | 0.451      |           |         |
| Grade          |            |           |         |            |           |         |
| I-II           |            |           |         |            |           |         |
| III-IV         | 1.411      | 1.074     | 1.853   | 0.013      | 1.669     | 1.235   | 2.257   | 0.001      |
| T stage        |            |           |         |            |           |         |
| T1-2           |            |           |         |            |           |         |
| T3-4           | 1.388      | 1.080     | 1.785   | 0.010      |           |         |
| Laterality     |            |           |         |            |           |         |
| Left           |            |           |         |            |           |         |
| Right          | 1.099      | 0.864     | 1.397   | 0.443      |           |         |
| Histologic type|            |           |         |            |           |         |
| CP             |            |           |         |            |           |         |
| CC             | 0.848      | 0.537     | 1.339   | 0.479      | 0.706     | 0.440   | 1.132   | 0.148      |
| CD             | 1.157      | 0.487     | 2.746   | 0.742      | 0.723     | 0.300   | 1.743   | 0.471      |
| PL             | 2.767      | 1.167     | 6.557   | 0.021      | 2.492     | 1.036   | 5.994   | 0.041      |
| Tumor size, cm |            |           |         |            |           |         |
| ≥4             |            |           |         |            |           |         |
|       | 4-7 | 1.125 | 0.683 | 1.851 | 0.644 |
|-------|-----|-------|-------|-------|-------|
| 7     | 1.323| 0.821 | 2.132 | 0.250 |

**N stage**

| N    |       |       |       |       |       |
|------|-------|-------|-------|-------|-------|
| N0   |       |       |       |       |       |
| N1   | 1.791 | 1.378 | 2.328 | 0.000 | 1.388 | 1.049 | 1.838 | 0.022 |

**Surgery**

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| No    |       |       |       |       |       |       |       |       |
| Yes   | 0.416 | 0.313 | 0.552 | 0.000 | 0.394 | 0.284 | 0.546 | 0.000 |

**Radiotherapy**

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| No    |       |       |       |       |       |       |       |       |
| Yes   | 1.103 | 0.862 | 1.411 | 0.438 |

**Chemotherapy**

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| No    |       |       |       |       |       |       |       |       |
| Yes   | 1.463 | 1.128 | 1.898 | 0.004 |

**Brain metastasis**

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| No    |       |       |       |       |       |       |       |       |
| Yes   | 2.315 | 1.575 | 3.403 | 0.000 | 1.801 | 1.201 | 2.700 | 0.004 |

**Liver metastasis**

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| No    |       |       |       |       |       |       |       |       |
| Yes   | 1.960 | 1.349 | 2.847 | 0.000 |

**Lung metastasis**

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| No    |       |       |       |       |       |       |       |       |
| Yes   | 2.261 | 1.771 | 2.887 | 0.000 | 1.745 | 1.342 | 2.269 | 0.000 |

**Insurance status**

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| No    |       |       |       |       |       |       |       |       |
| Yes   | 1.227 | 0.628 | 2.396 | 0.549 |

**Marital status**

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| No    |       |       |       |       |       |       |       |       |
| Yes   | 0.994 | 0.768 | 1.286 | 0.961 |
BM: bone metastasis, RCC: renal cell carcinoma, CP: chromophobe, CC: clear cell, CD: collecting duct, PL: papillary

Figures

Figure 1
The workflow describing the schematic overview of the project.
Figure 2

Nomogram to estimate the risk of BM in patients with RCC.

Figure 3

ROC curves (A), calibration curves (B), and DCA (C) of the training cohort.
Figure 4

ROC curves (A), calibration curves (B), and DCA (C) of the validation cohort.

Figure 5

Comparison of AUC between diagnostic nomogram and each independent predictor in the training cohort (A) and the validation cohort (B).
Figure 6

Survival curves for each independent prognostic factor in the training cohort. CP: chromophobe, CC: clear cell, CD: collecting duct, PL: papillary.

Figure 7

coxph regression

N stage
Brain metastasis
Histologic type
Grade
Lung metastasis
Surgery

Total points to outcome nomogram:

Pr(future < 12)
Pr(future < 24)
Pr(future < 36)
Figure 8

(A) Receiver operating characteristic curves of 1-, 2-, and 3-years in the training cohort; (B) The Kaplan-Meier survival curve of the training cohort; (C) Receiver operating characteristic curves of 1-, 2-, and 3-years in the validation cohort; (D) The Kaplan-Meier survival curve of the validation cohort.
Figure 9

The receiver operating characteristic curves of nomogram and all independent predictors at 1- (A), 2- (B), and 3-years (C) in the training cohort and at 1- (D), 2- (E), and 3-years (F) in the validation cohort.
Figure 10

(A) The calibration curves of the prognostic nomogram in the training cohort; (B) The calibration curves of the prognostic nomogram in the validation cohort; (C) The decision curve analysis of the prognostic nomogram in the training cohort; (D) The decision curve analysis of the prognostic nomogram in the validation cohort.